Rationale for Double Renin-Angiotensin-Aldosterone System Blockade

American Journal of Cardiology

Volumn 100, Issue 3 SUPPL., 2007, Pages

  Unger, Thomas ^a   Stoppelhaar, Martina ^a,b  

^a DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; IRBESARTAN; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; PROSTACYCLIN; RAMIPRIL; TELMISARTAN;

ACUTE HEART INFARCTION; ADIPOCYTE; ARTERY DISEASE; ARTICLE; BLOOD PRESSURE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; COUGHING; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLUCOSE METABOLISM; HEART FAILURE; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; META ANALYSIS; METABOLIC SYNDROME X; MONOTHERAPY; MORBIDITY; MORTALITY; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; STROKE; SYSTEMATIC REVIEW; TREATMENT DURATION; WEIGHT GAIN;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS; RENIN-ANGIOTENSIN SYSTEM;

EID: 34547129852     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.05.011     Document Type: Article

References (49)

1. de Gasparo M., Catt K.J., Inagami T., Wright J.W., and Unger T. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52 (2000) 415-472
2. Johnston C.I. Angiotensin II type 1 receptor blockade: a novel therapeutic concept. Blood Press 1 suppl (2000) 9-13
3. 2 receptor-a matter of love and hate. Peptides 26 (2005) 1401-1409
4. 1 receptor in the cardiovascular continuum. Eur Heart J 6 suppl H (2004) H3-H9
5. Erdös E.G. Angiotensin I converting enzyme. Circ Res 36 (1975) 247-255
6. Unger T., Ganten D., Lang R.E., and Schölkens B.A. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors?. Studies with the two different compounds, Hoe498 and MK421, in spontaneously hypertensive rats. J Cardiovasc Pharmacol 6 (1984) 872-880
7. Cohen M.L., and Kurz K.D. Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK421. J Pharmacol Exp Ther 220 (1982) 63-69
8. Unger T., Demmert G., and Fleck T. Role of tissue converting enzyme inhibition for the antihypertensive action of Hoe498 and MK421 in spontaneously hypertensive rats. [abstract]. Naunyn Schmiedebergs Arch Pharmacol 325 suppl (1984) 216
9. Richer C., Doussau M.P., and Giudicelli J.F. MK421 and prevention of genetic hypertension in young spontaneously hypertensive rats. Eur J Pharmacol 79 (1982) 23-29
10. Boomsma F., de Bruyn J.H.B., Derkx F.H.M., and Schalecamp M.A.D.H. Opposite effects of captopril on angiotensin I-converting enzyme "activity" and "concentration": relation between enzyme inhibition and long-term blood pressure response. Clin Sci 60 (1981) 491-498
11. Neal B., MacMahon S., Chapman N., and Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356 (2000) 1955-1964
12. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987) 1429-1435
13. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
14. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic in patients with reduced left ventricular ejection fractions. N Engl J Med 327 (1992) 685-691
15. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown Jr. E.J., Cuddy T.E., Davis B.R., Geltman E.M., Goldman S., Flaker G.C., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement trial. N Engl J Med 327 (1992) 669-677
16. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342 (1993) 821-828
17. Køber L., Torp-Pedersen C., Carlsen J.E., Bagger H., Eliasen P., Lyngborg K., Videbaek J., Cole D.S., Auclert L., Pauly N.C., and Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333 (1995) 1670-1676
18. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G., and Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
19. Henriksen E.J., and Jacob S. Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J Cell Physiol 196 (2003) 171-179
20. Urata H., Healy B., Stewart R.W., Bumpus F.M., and Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 66 (1990) 883-890
21. MacFadyen R.J., Lee A.F.C., Morton J.J., Pringle S.D., and Struthers A.D. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?. Heart 82 (1999) 57-61
22. Cleland J.G.F., Dutka D.P., and Ward S. Effects of enalapril on clinical, non-invasive haemodynamics and neuroendocrine indices in elderly patients (>75 years) with heart failure. Cardiology in the Elderly 4 (1996) 131-137
23. Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L., and CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 82 (1990) 1730-1736
24. Sigurdsson A., and Swedberg K. The role of neurohormonal activation in chronic heart failure and postmyocardial infarction. Am Heart J 132 (1996) 229-234
25. Huang X.R., Chen W.Y., Truong L.D., and Lan H.Y. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 14 (2003) 1738-1747
26. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 89 suppl 2A (2002) 3A-9A
27. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
28. Suzuki Y., Ruiz-Ortega M., Lorenzo O., Ruperez M., Esteban V., and Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 35 (2003) 881-900
29. 1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 44 (2004) 362-368
30. Turnbull F., and Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 (2003) 1527-1535
31. Lindholm L.H., Ibsen H., Borch-Johnsen K., Olsen M.H., Wachtell K., Dahlöf B., Devereux R.B., Beevers G., de Faire U., Fyhrquist F., et al., LIFE Study Group. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 20 (2002) 1879-1886
32. Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., Michelson E.L., Olofsson B., Ostergren J., Yusuf S., Pocock S., and CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
33. Julius S., Kjeldsen S.E., Weber M., Brunner H.R., Ekman S., Hansson L., Hua T., Laragh J., McInnes G.T., Mitchell L., et al., VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
34. Picard F., and Auwerx J. PPAR-γ and glucose homeostasis. Annu Rev Nutr 22 (2002) 167-197
35. Pershadsingh H.A., Benson S.C., Ho C.I., Avery M.A., and Kurtz T.W. Identification of PPAR-γ activators that do not promote fluid retention and edema: implications for treating insulin resistant hypertension and the metabolic syndrome. [abstract]. In: Webb P., Evans R.M., and Hsueh W.H. (Eds). Proceedings of the Endocrine Society Symposium on Nuclear Receptors in Cardiovascular Disease: Hot Topics in Endocrinology (2003), The Endocrine Society, Chevy Chase, MD 29 October 8-12, 2003; San Diego, California
36. Schupp M., Janke J., Clasen R., Unger T., and Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferators-activated receptor-γ activity. Circulation 109 (2004) 2054-2057
37. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., Qi N., Wang J., Avery M.A., and Kurtz T.W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 43 (2004) 993-1002
38. Clasen R., Schupp M., Foryst-Ludwig A., Sprang C., Clemens M., Krikov M., Thöne-Reinecke C., Unger T., and Kintscher U. PPARγ-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46 (2005) 137-143
39. Schupp M., Lee L.D., Frost N., Umbreen S., Schmidt B., Unger T., and Kintscher U. Regulation of peroxisome proliferator-activated receptor γ activity by losartan metabolites. Hypertension 47 (2006) 586-589
40. Israili Z.H. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 14 suppl 1 (2000) S73-S86
41. Schupp M., Clemenz M., Gineste R., Witt H., Janke J., Helleboid S., Hennuyer N., Ruiz P., Unger T., Staels B., and Kintscher U. Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity. Diabetes 54 (2005) 3442-3452
42. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 115 suppl 8A (2003) 42S-48S
43. Sugimoto K., Qi N.R., Kazdova L., Pravenec M., Ogihara T., and Kurtz T.W. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47 (2006) 1003-1009
44. Ruilope L.M., Rosei E.A., Bakris G.L., Mancia G., Poulter N.R., Taddei S., Unger T., Volpe M., Waeber B., and Zannad F. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press 14 (2005) 196-209
45. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P., and Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria [IRMA-2] Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
46. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Ritz E., Atkins R.C., Rohde R., Raz I., and Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
47. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., Remuzzi G., Snapinn S.M., Zhang Z., Shahinfar S., and RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
48. Teo K., Yusuf S., Sleight P., Anderson C., Mookadam F., Ramos B., Hilbrich L., Pogue J., Schumacher H., and ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 148 (2004) 52-61
49. Unger T. The ongoing telmisartan alone and in combination with Ramipril Global Endpoint Trial Program. Am J Cardiol 91 suppl 10A (2003) 28G-34G